Pro Medicus Ltd (ASX: PME) shares have dropped more than 20% since their peak a few weeks ago. Is this an opportunity to buy?

The station sponsors some live performances and has two shows that play recordings of concerts in the region: “WMHT Live” and ...

Map Reading for night navigation at the Mountain Mammoth Adventure Race Challenging mountain biking stages are part of all ARWS Africa race ...

Medicus Pharma (MDCX) announces a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell ...

Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each ...

Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2 ...

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major ...

USA-based Medicus Pharma has announced a positive-trending interim analysis for the SKNJCT-003 Phase II study, which aims to treat non-invasively basal cell carcinoma of the skin (BCC).

Wasatch International Growth Fund—Investor Class was down -7.22% but outperformed MSCI AC (All Country) World ex USA Small ...

Pro Medicus (ASX: PME) has signed a seven-year, A$40 million contract with LucidHealth, a leading US-based radiology provider ...

Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational ...